-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Dementia is characterized by a gradual decline in cognitive ability and daily activities.
The two main causes of dementia are Alzheimer's disease (AD) and vascular dementia
.
Some studies have shown that the use of systemic hormones to treat menopausal vasomotor symptoms is positively correlated with the development of dementia in postmenopausal women
.
These studies include the Women’s Health Initiative Memory Study, a randomized, double-blind, placebo-controlled clinical trial that reported that women over 65 years of age doubled their risk of developing dementia after using hormone therapy
It reported 65 or more years of age women using hormone therapy risk of dementia doubles troubles reported 65 risk over the age of women using hormone therapy troubles dementia doubles
In addition, other studies have shown that there is a negative or no correlation between hormone therapy and dementia
.
The international guidelines on the side effects of hormone therapy (National Institute of Health and Care Excellence [NICE] guidelines) believe that there is a lack of evidence related to dementia, and calls on researchers to conduct more research
Vaginal estrogen is the main method to treat common symptoms of postmenopause, such as vaginal dryness, irritation, dysuria, and urinary urgency and incontinence, and there have not been any serious adverse events
.
However, we currently know little about the dose-dependent effects of vaginal estradiol use and the risk of dementia
Recently, researchers evaluated the relationship between cumulative doses of vaginal estradiol tablets and dementia in a case-control study nested in a national cohort of Danish women who were age at the start of the study.
Between the ages of 50 and 60, no systematic hormone therapy is used
.
Each case was age-matched with 10 female control groups
According to the cumulative dose of vaginal estradiol tablets, the risk ratio (HR) of all-cause dementia (A) and Alzheimer's disease (B)
According to the cumulative dose of vaginal estradiol tablets, the risk ratio (HR) for all-cause dementia (A) and Alzheimer’s disease (B) is based on the cumulative dose of vaginal estradiol tablets, all due to dementia (A) and Alzheimer’s Hazard ratio (HR) of Haimer's disease (B)A total of 4574 dementia patients in the study were matched with 45740 control groups
.
The results showed that the cumulative use of vaginal estradiol tablets was not associated with all-cause dementia ; the adjusted hazard ratio for low-dose (<750 micrograms) was 1.
Cumulative use of vaginal estradiol tablets has nothing to do with all-cause dementia.
Original source:
Original source:Nelsan Pourhadi et al.
Nelsan Pourhadi et al.
Leave a message here
